GABA-B agonist supplement
Phenibut
A 2024 review reports a plasma half-life of 5.3 h for phenibut after a single 250 mg oral dose in healthy volunteers; the app lists 5 h.1
Phenibut after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.
Drawn from the half-life in the app's model, ~5 h. The model's figures
- Compound
- Phenibut
- Symbol
- PHB
- Family
- Supplements
- Parts
- 13
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Phenibut (β-phenyl-γ-aminobutyric acid) is described by Gurley and colleagues as a structural GABA analogue and agonist.1 Lapin, in CNS Drug Reviews in 2001, describes it as a neuropsychotropic drug "discovered and introduced into clinical practice in Russia in the 1960s".2 Lapin writes that it "is widely used in Russia to relieve tension, anxiety, and fear, to improve sleep in psychosomatic or neurotic patients".2 Cohen and colleagues (Clinical Toxicology, 2022) state that the US Food and Drug Administration "has never approved the use of phenibut as a prescription medication, but the drug is available over-the-counter in dietary supplements".3 The app files phenibut as a supplement (GABA-B agonist) and grades the evidence as moderate; the app's own notes tag it as high-risk because of tolerance, dependence and withdrawal liability. The sections below draw on systematic reviews, case reports, a poison center series, a supplement analysis, an FDA notice and the WADA list.
How it works
Sources in this part
Kupats and colleagues (Pharmacopsychiatry, 2020) write that phenibut exerts anxiolytic and antinociceptive effects "by acting on the GABAB receptor and the α2-δ subunit of voltage-dependent calcium channels".4 Lapin's review says it acts "primarily at GABA(B) and, to some extent, at GABA(A) receptors", and "also stimulates dopamine receptors".2 Lapin adds that its psychopharmacological activity "is similar to that of baclofen, a p-Cl-derivative of phenibut".2 These are descriptions from reviews; the 2024 review by Gurley and colleagues states that "Pharmacokinetic and pharmacodynamic data is virtually non-existent in English peer-reviewed literature and is scarce even in Russian".1 The same review says it is "postulated" that the mechanisms of addiction relate to the drug's "short half-life and its impact on GABA and dopamine systems".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~5 h
- Bioavailability
- 99%
- Typical dose
- 250–500 mg/dose
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The second column of the table holds the app's figures, beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~5 h | Plasma half-life of 5.3 h after a single 250 mg oral dose in healthy human volunteers, as reported in the 2024 review by Gurley and colleagues1 |
| Bioavailability | 99% | None of the texts read gives a bioavailability figure; the 2024 review reports that 65% of a single 250 mg oral dose was excreted unchanged in the urine1 |
| Time to peak | ~2 h | None of the texts read gives a time to peak |
| Duration | ~12 h | None of the texts read gives a duration of effect; the 2024 review says brain concentrations of phenibut in humans "appear to remain stable for at least 6 hours"1 |
| Brain exposure | Not in the app | The 2024 review states "It is anticipated that only about 0.1% of a phenibut dose reaches the brain, although in the very young and elderly this value may be higher"; "No evidence of bioaccumulation has been reported"1 |
| Metabolism | Not in the app | Soviet findings: not metabolised after intravenous dosing in rats or rabbits; two Russian fact sheets: up to 95% biotransformed in the liver1 |
Deeper analysis: the 2024 narrative review by Gurley and colleagues
Gurley and colleagues (Basic and Clinical Pharmacology and Toxicology, 2024) describe their work as a "narrative review" and report searching PubMed, Web of Science and Google Scholar.1 Of 89 non-duplicate citations, 36 were available in Russian only and were excluded from further analysis; 31 articles, including case reports and reviews, were considered relevant.1 The 5.3 h figure comes from one sentence in the review, which gives neither the design nor the number of volunteers.1 The authors state that "even the available Russian sources often contradict each other, i.e., on the matter of bioaccumulation and metabolism of phenibut in the liver".1 Their stated limitation is the lack of English peer-reviewed pharmacokinetic data and of access to full texts of Russian-language papers, which "could potentially introduce some bias".1 Funding came in part from an Institutional Development Award from the National Institute of General Medical Sciences, and the authors declare no potential conflict of interests.1
Human studies
A ClinicalTrials.gov search for "phenibut" returned 0 studies. Among the 20 PubMed records listed for "phenibut" (302 matched), none was a controlled trial in people; they were reviews, case reports, a letter, a veterinary case and a supplement analysis. The human evidence read for this compound is therefore systematic reviews of trials and case reports, a poison center series and single case reports, summarised in the table.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Kupats and colleagues, Pharmacopsychiatry 20204 | Systematic review of 11 clinical trials and 14 case reports | 583 patients in the trials; 16 patients in the case reports | Case-report doses 0.5-100 g/day; trial doses and lengths not in the PubMed record | Adverse events in "only 5.66% of patients" in the trials; most reported side effect somnolence (1.89%)4 |
| Weleff and colleagues, Journal of Addiction Medicine 20235 | Systematic review of published toxicity and withdrawal cases (Medline, Embase, Cochrane Library) | 62 cases from 36 studies; 80.7% male; average age 30.9 years (SD, 13.2 years; range, 0-71 years) | Doses not in the PubMed record; hospital stay averaged 5.0 days (n = 25; range, 1-25 days) for toxicity and 7.7 days (n = 20; range, 0-30 days) for withdrawal | 48.7% of toxicity cases required intubation; 95.7% of withdrawal cases reported daily use5 |
| McCabe and colleagues, American Journal of Emergency Medicine 20196 | Observational analysis of poison center exposure calls, Minnesota | 56 exposure calls from January 2000 through December 2018 | Doses not in the PubMed record | 11 patients (19.6%) intubated; "No patients died due to reported phenibut use"; coingestants documented in 35.7%6 |
| Stewart and colleagues, Cureus 20247 | Systematic review of case reports of withdrawal, PubMed, 2010 to October 2023 | 15 articles included; average age 31.8 years; 13 cases (87%) male | Average 13.6 g/day, range 1.5 to 28.5 g/day | Most common history was alcohol or drug abuse (73%); most common withdrawal symptoms insomnia, hallucinations and muscle abnormalities (8 cases, 53% each)7 |
| Samokhvalov and colleagues, BMJ Case Reports 20138 | Single case report | One 35-year-old man with prior alcohol, opioid and benzodiazepine use | 8 g phenibut and 18 g kratom per day; phenibut for 10 months | Tolerance and withdrawal symptoms within 3-4 h of last use; phenibut substituted with baclofen over 9 weeks8 |
| Arndt and Gray, Journal of Analytical Toxicology 20219 | Single case report with autopsy and toxicology | One 26-year-old man found dead at home with phenibut containers on scene | Not stated in the PubMed record | "Autopsy findings and routine toxicology testing were generally unremarkable"; phenibut confirmed in blood and urine by LC-MS/MS9 |
Deeper analysis: Kupats and colleagues, systematic review of trials and case reports
Kupats and colleagues, of the Latvian Institute of Organic Synthesis and Riga Stradins University, reviewed "11 phenibut clinical trials (583 patients)" together with 14 case reports (16 patients), and note that phenibut has been widely prescribed "in Eastern Europe for more than half a century".4 In the case reports the symptoms included "cardiovascular effects, insomnia, anxiety and agitation, hallucinations, and depressed level of consciousness".4 The trials showed adverse events in 5.66% of patients, with somnolence reported in 1.89%.4 The authors write that "There are discrepancies in the reported side effects of phenibut in clinical trials compared to those reported in cases of online-purchased phenibut dependence and intoxication".4 Their conclusion reads that "at therapeutic doses, phenibut is safe and well tolerated with minor adverse effects, but questions regarding the quality of phenibut obtained online and the contribution of alcohol and other drug abuse to phenibut dependence and intoxication remain open".4 The PubMed record states "The authors declare no conflict of interest" and gives no funder; it does not describe the individual trials, their doses or their lengths, so the trial-level results are not reported here.4
Deeper analysis: Weleff and colleagues, systematic review of toxicity and withdrawal cases
Weleff and colleagues (Yale University, Cleveland Clinic, Mayo Clinic and Case Western Reserve University, 2023) searched "Medline (Ovid), Embase (Ovid), and Cochrane Library databases".5 Of the cases, "86.8% reported obtaining phenibut online, and 63.2% reported concomitant substance use with other addictive agents", with benzodiazepines and alcohol the most combined drugs.5 Toxicity cases most often showed "altered mental status, somnolence, psychosis, and movement disorders".5 Withdrawal cases most often showed "anxiety, irritability or agitation, insomnia, and psychosis", and 16 (69.6%) required multiple medications for treatment.5 The authors conclude that the seriousness of the presentations and the variety of medications used "reflects the potential dangers of phenibut use and the need for systematized treatment protocols".5 The authors report no conflicts of interest; the PubMed record states no funder and does not include a limitations section.5
Deeper analysis: McCabe and colleagues, poison center exposure calls
McCabe and colleagues, of Regions Hospital, Hennepin County Medical Center and the Minnesota Poison Control System, analysed all phenibut exposure calls from January 2000 through December 2018.6 There were 56 calls, 48 (85.7%) within the last five years of the period.6 "Over 50% of patients had CNS effects and 10.7% had withdrawal concerns"; 27 patients (48%) had abuse as the reason for use and 13 (23%) used it to treat anxiety.6 No patients died, and 11 (19.6%) were intubated.6 The authors conclude that calls "have increased over the past five years".6 The PubMed record gives no funding or conflict-of-interest statement and no limitations; calls to a poison center are reports, not a count of all exposures in the population.6
Deeper analysis: Stewart and colleagues, systematic review of withdrawal case reports
Stewart and colleagues (Cureus, 2024) identified "25 cases published from 2010 to October 2023" in the PubMed database, and 15 articles were included.7 In those cases the average dose was 13.6 g/day, and withdrawal symptoms included insomnia, hallucinations and muscle abnormalities in 8 of 15 cases each.7 The authors cite reports that patients "develop a tolerance in as little as a week".7 Their stated limitations include "the small number of cases available, along with the limited age range and the gender of reporting patients", and that "The doses reported are based on the dosages reported by the patient".7 They add that "Quality factors such as the purity of phenibut are not known".7 The authors state that no financial support was received from any organization for the work and that they have no financial relationships with organisations that might have an interest in it.7
Deeper analysis: single case reports
Samokhvalov and colleagues (BMJ Case Reports, 2013), at the Centre for Addiction and Mental Health in Toronto, write that "We present a rare case of phenibut dependence".8 The patient reported past opioid and benzodiazepine use, had a history of alcohol dependence, and was taking kratom (18 g per day) alongside phenibut (8 g per day).8 Arndt and Gray (Harris County Institute of Forensic Sciences, 2021) report the autopsy of a 26-year-old man in whom routine toxicology was "generally unremarkable" and phenibut was confirmed by a validated qualitative LC-MS/MS method.9 The PubMed record for Arndt and Gray states no funder, conflicts, limitations or cause of death; the full text of Samokhvalov and colleagues states "Competing interests: None" and has no funder statement or limitations section.8,9
Doses reported in studies and on labels
Sources in this part
No label for a medicine containing phenibut was identified in DailyMed. The figures below come from reviews, case reports and a supplement analysis.
| Setting | Dose reported | Context and reference |
|---|---|---|
| Single oral dose, healthy volunteers | 250 mg | Plasma half-life of 5.3 h; 65% excreted unchanged in urine1 |
| Later studies cited by the 2024 review | 250 mg to 500 mg/day | "Subsequent studies reported usage of doses ranging from 250 mg to 500 mg/day"1 |
| Recommended daily dose cited in the 2020 systematic review | 0.25-2 g/day | Called the "recommended daily dose" in the review of 11 trials and 14 case reports, which says the case-report doses (0.5-100 g/day) were "much higher"4 |
| Russian drug fact sheets (two) | 2500 mg maximum daily intake | As reported by Gurley and colleagues, who read two fact sheets in Russian1 |
| Russian pharmaceutical tablet | 250 mg per tablet | Described as "a typical 250 mg pharmaceutical tablet manufactured in Russia"3 |
| US supplements before FDA warnings | 484 mg and 487 mg per serving | Two of four brands contained phenibut; measured by mass spectrometry3 |
| US supplements after FDA warnings | 21 mg to 1,164 mg per serving | All four brands contained phenibut3 |
| Case reports of dependence and intoxication | 0.5-100 g/day | 14 case reports, 16 patients4 |
| Withdrawal case reports | Average 13.6 g/day, range 1.5 to 28.5 g/day | 15 articles, doses as reported by patients7 |
| Study of 105 users cited by the 2024 review | Mean (± standard deviation) dose of phenibut ingestion 2430 ± 1620 mg | Cited from Owen and colleagues; the review adds that only three users reported consuming as little as 500 mg daily and that in some cases a daily intake of 9000 mg was reported1 |
| The app | 250–500 mg/dose | Typical dose range in the app's entry |
Side effects reported
Sources in this part
In the trial literature, Kupats and colleagues report adverse events in 5.66% of patients and somnolence in 1.89%.4 Gurley and colleagues list "drowsiness, lethargy, agitation, tachycardia, and confusion" among documented side effects.1 They write that intoxication "is usually dose dependent", with cases reported from doses "as low as 1000 mg daily and durations less than 10 days" up to doses "nearing 50 000 mg daily", and that symptoms are usually "clinically resolved within hours to days", but "the sequelae of poisoning may last for weeks or months".1 The same review states that "no specific treatment for phenibut intoxication exists" and that no prospective assessments of drug interactions have been conducted.1 In the Weleff review, 48.7% of toxicity cases required intubation; in the Minnesota poison center series 11 patients (19.6%) were intubated and none died.5,6 Gurley and colleagues, citing other work, give "Life-threatening or disabling effects occurred in 12.6% of cases; 80 cases (6.2%) resulting in a coma and three cases in death".1 Of withdrawal cases, 95.7% reported daily use, and the most common symptoms were "anxiety, irritability or agitation, insomnia, and psychosis".5 Gurley and colleagues describe "the first neonatal case of phenibut withdrawal requiring pharmacological intervention" after maternal use during pregnancy, and a group of five teenagers whose poisoning "required intubation and subsequent treatment".1
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for phenibut. Gurley and colleagues write that the Russian drug fact sheets carry a warning about "monitoring liver function with prolonged usage".1 Two case reports of overdose that measured ALT and AST "found no evidence of overt hepatotoxicity", and the review adds that fatty liver disease is rarely associated with substantially raised aminotransferases; it also reports moderate microvesicular hepatic steatosis in a deceased 26-year-old man in whom phenibut was detected post mortem, and notes that the Russian fact sheets list non-alcoholic fatty liver disease as a potential adverse effect of overdose at doses of ≥7000 mg/day.1 Stewart and colleagues write that "phenibut does not show up on any standard drug tests, and no commercial tests are available for its detection".7 Arndt and Gray detected phenibut in blood and urine after death by liquid chromatography tandem mass spectrometry.9
Regulatory and anti-doping status
The FDA constituent update of 16 April 2019 states that the FDA "issued 3 warning letters to companies whose products are marketed as dietary supplements and labeled to contain phenibut".10 The update states that "Phenibut does not meet the definition of a dietary ingredient Under the Federal Food, Drug, and Cosmetic Act (FD&C Act)" and that "Products labeled as dietary supplements that list phenibut as a dietary ingredient are misbranded".10 Gurley and colleagues write that "prohibited status in some European countries (i.e., France, Italy and Lithuania), the U.S. and Australia" has not stopped online sales.1 Stewart and colleagues instead write that phenibut "is a controlled substance in Australia and banned in the countries of Hungary, Italy, and Lithuania"; the two reviews differ on the countries listed.7 In the text of the WADA 2026 Prohibited List retrieved for this compound, the word phenibut does not appear.11 The list's S0 class covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List", and the list text does not say whether phenibut falls under it.11
Deeper analysis: Cohen and colleagues, phenibut content of supplements
Cohen and colleagues (Cambridge Health Alliance, Harvard Medical School, the University of California San Francisco and NSF International) analysed four US brands of dietary supplements labelled as containing phenibut by "liquid chromatography time-of-flight mass spectrometry".3 Before the FDA warnings two of the four contained phenibut (484 mg and 487 mg per serving); afterwards all four did (21 mg to 1,164 mg per serving).3 The authors report that the quantity "increased in 3 of 4 brands of over-the-counter phenibut supplements" after the FDA advisory, and that amounts per dose were "as much as 450% greater than a typical 250 mg pharmaceutical tablet manufactured in Russia".3 The study covers four brands only, so it does not describe the market as a whole; the PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and states no funder, conflicts or limitations.3
What is not known
Sources in this part
- A ClinicalTrials.gov search for "phenibut" returned 0 studies, and no controlled trial in people was identified in the PubMed records listed for the search.
- The trial-level data behind the 11 trials reviewed by Kupats and colleagues (doses, lengths, comparators) are not in the PubMed record read.4
- The source of the 5.3 h half-life is a single sentence in a narrative review, and the authors say pharmacokinetic data are "virtually non-existent in English peer-reviewed literature".1
- The texts read give no bioavailability figure and no time to peak to set beside the app's 99% and about 2 h.
- The 2024 review reports that Soviet findings describe phenibut as largely excreted unchanged in the urine, while two Russian manufacturers' fact sheets state that up to 95% undergoes hepatic biotransformation.1
- The contribution of product quality and of other substances to the dependence and intoxication cases remains open, in the Kupats authors' words.4
Frequently asked questions
What is the half-life of phenibut?
What receptors does phenibut act on?
Where was phenibut developed?
Lapin states that phenibut was discovered and introduced into clinical practice in Russia in the 1960s.2
Is phenibut approved by the FDA?
Is phenibut banned by WADA?
Are there controlled trials of phenibut in people?
A ClinicalTrials.gov search for "phenibut" returned 0 studies, and no controlled trial in people was identified in the PubMed records listed. A 2020 systematic review reviewed 11 phenibut clinical trials with 583 patients.4
What side effects were reported in phenibut clinical trials?
What are the reported symptoms of phenibut withdrawal?
Does phenibut show up on standard drug tests?
Did phenibut content in supplements change after the FDA warnings?
In an analysis of four brands, the quantity of phenibut increased in 3 of 4 after the FDA warnings.3
More in Supplements
References
- Gurley BJ, Koturbash I. Phenibut: A drug with one too many "buts". Basic Clin Pharmacol Toxicol 2024. PMC11583343
- Lapin I. Phenibut (β-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 2001;7(4):471-81. PMID 11830761
- Cohen PA, et al. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila) 2022;60(4):486-488. PMID 34550038
- Kupats E, et al. Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports. Pharmacopsychiatry 2020;53(5):201-208. PMID 32340063
- Weleff J, et al. Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review. J Addict Med 2023;17(4):407-417. PMID 37579098
- McCabe DJ, et al. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med 2019;37(11):2066-2071. PMID 30878413
- Stewart C, et al. A Systematic Review of Phenibut Withdrawals. Cureus 2024. PMC11456982
- Samokhvalov AV, et al. Phenibut dependence. BMJ Case Rep 2013. PMC3604470
- Arndt C, Gray TR. Phenibut, a GABAB Agonist, Detected in a Fatality. J Anal Toxicol 2021. PMID 34520515
- US Food and Drug Administration. FDA Acts on Dietary Supplements Containing DMHA and Phenibut. Constituent update, 16 April 2019. FDA constituent update
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list